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ABSTRACT
The PI3K/AKT/mTOR pathway is frequently activated in advanced prostate 
cancer, due to loss of the tumour suppressor PTEN, and is an important axis for drug 
development. We have assessed the molecular and functional consequences of pathway 
blockade by inhibiting AKT and mTOR kinases either in combination or as individual 
drug treatments. In established prostate cancer cell lines, a decrease in cell viability 
and in phospho-biomarker expression was observed. Although apoptosis was not 
induced, a G1 growth arrest was observed in PTEN null LNCaP cells, but not in BPH1 or 
PC3 cells. In contrast, when the AKT inhibitor AZD7328 was applied to patient-derived 
prostate cultures that retained expression of PTEN, activation of a compensatory Ras/
MEK/ERK pathway was observed. Moreover, whilst autophagy was induced following 
treatment with AZD7328, cell viability was less affected in the patient-derived cultures 
than in cell lines. Surprisingly, treatment with a combination of both AZD7328 and two 
separate MEK1/2 inhibitors further enhanced phosphorylation of ERK1/2 in primary 
prostate cultures. However, it also induced irreversible growth arrest and senescence.
Ex vivo treatment of a patient-derived xenograft (PDX) of prostate cancer with 
a combination of AZD7328 and the mTOR inhibitor KU-0063794, significantly reduced 
tumour frequency upon re-engraftment of tumour cells.
The results demonstrate that single agent targeting of the PI3K/AKT/mTOR pathway 
triggers activation of the Ras/MEK/ERK compensatory pathway in near-patient samples. 
Therefore, blockade of one pathway is insufficient to treat prostate cancer in man.
INTRODUCTION
Prostate cancer is the most common cancer in men, 
and the second most common cause of cancer death in 
men in the UK (Cancer Research UK, 2014). Advanced 
prostate tumours initially respond well to androgen 
deprivation therapy (ADT). However, in most cases, 
ADT ultimately fails and castration resistant prostate 
cancer (CRPC) emerges, which is almost inevitably 
fatal [1]. Although novel therapeutic agents, such 
as abiraterone and enzalutamide have demonstrated 
improved overall survival in metastatic CRPC, new 
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therapies are urgently needed [2–4]. There is also a 
growing realisation that early adoption of chemotherapy 
either before or with hormone therapy, results in greatly 
increased survival [5].
The PI3K/AKT/mTOR pathway is over-activated 
in many human cancers, including prostate cancer, and 
has emerged as a target for small molecule therapies 
[6–8]. However, inhibition of the PI3K pathway alone 
has proven to be insufficient for treatment of cancer, 
due to the existence of feedback loops and cross-talk 
with other pathways, including the Ras/Raf/MEK/ERK 
[9–11], and androgen receptor signalling pathways [8, 
12, 13]. Therefore, combined targeting of the PI3K/
AKT/mTOR and the Ras/MEK/ERK pathways has 
been proposed as an alternative approach in a range 
of different cancers, including multiple myeloma 
(MM), melanoma and prostate cancer [6, 14, 15]. In 
multiple myeloma, combined blockade of the PI3K and 
MAPK pathways resulted in significantly enhanced 
cell death in the majority of tested cell lines [14]. A 
combination of the mTORC1 inhibitor, rapamycin and 
the MEK inhibitor, PD325901 inhibited growth of both 
androgen-responsive (CWR22Rv1 and CASP 2.1) and 
androgen-independent (CASP 1.1) prostate cancer 
cell lines. Blockade of both pathways, using a novel 
sorafenib derivative, NSK-01105, was shown to reduce 
cell proliferation and induce apoptosis in LNCaP and 
PC3 cells, and xenografted tumours of the same cell 
lines [16].
Preclinical assessment of potential new prostate 
cancer therapies is routinely performed in a limited 
number of cell lines and xenografts derived from them. 
The acknowledged heterogeneity between responses in 
different patients is therefore not addressed and may 
be the cause of the high attrition rate in oncology drug 
development [17]. In general, such approaches allow 
measurements of drug efficacy, but can prove misleading 
in determining the clinical applicability of drugs and 
drug combinations. Additionally, the presence of cancer 
stem cells (CSCs), in a range of cancers including 
leukaemia [18], breast [19], brain [20], colon [21], 
pancreas [22], lung [23] and prostate [24–26], has been 
suggested to be responsible for therapy resistance [27]. 
In prostate cancer, basal phenotype CSCs, CD44+/α2β1
hi/
CD133+ are the most likely source of treatment-resistant 
cells, serving as a reservoir for tumour recurrence after 
castration therapy [24, 28, 29].
To address intra-tumour heterogeneity and differ-
ences between patients, we investigated the role of PI3K/
AKT/mTOR signalling in a range of prostate cancer 
primary cultures and PDXs. By measuring the signalling 
and cellular responses after treatment with small molecule 
inhibitors of the pathway, we demonstrate a surprising, but 
consistent disparity between the ‘standard’ cell line models 
and patient-derived cells.
RESULTS
Novel AKT and mTOR inhibitors reduce 
prostate cell viability
As AKT and mTOR kinases are crucial regulators 
of prostate cancer cell growth, proliferation and survival, 
treatment of high grade tumours with an AKT kinase 
inhibitor (AZD7328) and mTOR kinase inhibitor (KU-
0063794), both ATP-competitive small molecules, has been 
proposed as a promising treatment strategy in oncology 
[6–8]. To establish the efficacy of the small molecule 
inhibitors, two PTEN-positive cell lines, BPH1 (benign) 
and P4E6 (localised cancer) and two PTEN-negative cell 
lines LNCaP (lymph node metastasis) and PC3 (bone 
metastasis) were treated with a range of concentrations 
(0.01 – 30 μM) of AZD7328 or KU-0063794, for up to 
48 hours. An MTS assay was performed to investigate 
the effect of AZD7328 and KU-0063794 on cell viability. 
LNCaP cells were the most sensitive to both inhibitors 
with an EC50 of 0.4 μM (0.3-0.5) for AZD7328 and 1.03 
μM (0.8-1.3) for KU-0063794 (Table 1). PC3 cells were 
similarly susceptible to KU-0063794, but were 27 fold less 
sensitive to AZD7328 (11.0 μM). Although treatment with 
AZD7328 reduced the viability of both PTEN-negative cell 
lines, the PTEN-positive cells lines (BPH1 and P4E6) were 
less sensitive to the AKT inhibitor and their viability was 
only slightly reduced. Specifically, the EC50 for the KU-
0063794 were approximately 5 – 15 fold higher for BPH1 
(5.8 μM) and P4E6 (10.2 μM) in comparison to LNCaP and 
PC3 (Table 1). Taken together, these results suggest that 
AZD7328 and KU-0063794’s ability to reduce cell viability 
is dependent on PTEN status, with PTEN-negative cell lines 
being more susceptible to AKT and mTOR blockade.
To validate these findings in a ‘near-patient’ setting, 
primary cultures were generated from prostate cancer 
biopsies. Biopsies from patients with benign disease 
were used as normal controls. The cells were treated with 
increasing concentrations (1 – 50 µM) of AZD7328 or KU-
0063794 for up to 72 hours and cell viability was assessed. 
The results show that AZD7328 and KU-0063794 are less 
effective in patient-derived cultures (Supplementary Figure 
1) indicating that combined treatment should be considered.
As mTOR kinase is responsible for maintaining 
metabolic homeostasis, the effect of treatment was 
measured using trypan blue exclusion to assess viability, 
and in a larger cohort of patients (n=6). Primary cultures 
were treated with AZD7328 and KU-0063794, either 
alone or in combination. We observed a significant 
decrease in the viability (~ 30%) with 3 μM KU-0063794 
treatment at 24 and at 48 hours (P< 0.015) (Figure 1A). 
Interestingly, a significant decrease in cell viability was 
observed in the majority of samples following combined 
treatment with 3 μM of either inhibitor at 24 hours and 48 
hours (P < 0.006) (Figure 1A). Additionally, a significant 
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advantage of combination treatment over AZD7328 alone 
was observed at 48 hours. Importantly, these data show 
that there is variability in response to treatment between 
patients.
Since prostate epithelial cells are organised in 
a hierarchy [24, 29–31], the effect of treatment was 
assessed on the viability of Stem-like Cells (SC), Transit 
Amplifying (TA) and Committed Basal (CB) cells. 
Primary epithelial cancer cultures (derived from patients 
with Gleason 9, n=3 and Gleason 7 cancer, n=1) were 
treated with either 3 μM AZD7328, 3 μM KU-0063794 or 
a combination of 3 μM AZD7328 + 3 μM KU-0063794, 
for 72 hours. The cell subpopulations were isolated 
following treatment, and viability was assessed using 
trypan blue exclusion. Treatment with 3 μM AZD7328 
reduced the viability of stem-like cells in 3 of 4 samples 
with the highest reduction (78%), in a Gleason 9 sample 
(H149/12) (Figure 1B). Moreover, treatment with 3 μM 
KU-0063794 resulted in a decrease in the viability of 
SCs derived from all Gleason 9 samples, whilst stem 
cell numbers were not affected by treatment from the 
Gleason 7 culture. Interestingly, a combination of 3 μM 
AZD7328 + 3 μM KU-0063794 resulted in a significant 
decrease (P = 0.0044) in SC numbers in all cancer cultures 
(Figure 1B).
In contrast to the effect on stem cell numbers, 
TA and CB cell numbers were not affected with either 
inhibitor alone or a combination of both (Figure 1B). These 
results reflect prostate cancer intra tumoural heterogeneity 
as well as differences between patient samples further 
emphasizing the need for patient stratification.
Inhibition of AKT and mTOR does not induce 
cell cycle arrest in primary cultures
To determine whether the inhibitors directly 
influenced the cell cycle, two BPH and three cancer 
cultures were treated for 72 hours, with 5 μM AZD7328, 
5 μM KU-0063794, and a combination of 5 μM AZD7328 
+ 5 μM KU-0063794 and were subsequently analysed 
by flow cytometry. The results revealed no significant 
difference in cell cycle distribution (p value >0.3) 
(Figure 1C).
Expression of the tumour suppressor PTEN in 
prostate cancer patient cultures
Loss of the tumour suppressor gene, PTEN is 
observed in 40% of advanced prostate cancers [32, 33]. 
Given the importance of PTEN in regulating the activity of 
the PI3K pathway, we determined the status of the PTEN 
gene as well as expression, in our patient-derived cultures. 
DNA analysis was performed on 7 samples for which 
matched lymphocytes and tumour biopsies were available. 
As a mutational hot spot has been reported in exon 5 of 
the PTEN gene (http://atlasgeneticsoncology.org/Genes/
PTENID158.html), we focused our analysis on exon 5. 
The results showed that missense mutations were found 
in tumour DNA of three samples (H135/11, H224/12 and 
H278/13), but not in their corresponding lymphocytes 
(Supplementary Figure 2A). However, it is not clear 
whether those mutations have resulted in translation of 
a functional PTEN and be affecting functionality of the 
PTEN protein and this will need to be investigated further.
Next, we determined whether tumour cells showed 
loss of heterozygosity at the PTEN gene locus 10p23 
using two LOH probes (Table 2) described in Dahia et 
al [34]. LOH analysis using Probe 1 (dinucleotide repeat 
in PTEN intron 2 (AFMa086wg9) showed that 2/7 
samples (H135/11 and H377/13) were heterozygous and 
both cultures showed a relative loss of heterozygosity 
(expressed as reduction in peak intensity) in tumour 
DNA. Interestingly, the H135/11 sample which Had 
a missense mutation in exon 5 and LOH, showed a 
significant reduction in cell viability of stem-like cells 
following treatment with a combination of AZD7328 and 
KU-0063794, indicating higher susceptibility to the drugs. 
LOH analysis using probe 2 (G/T sequence polymorphism 
in PTEN intron 8) identified heterozygosity in a further 2 
samples (H224/12 and H237/12). However, only H224/12 
showed a relative loss of heterozygosity in the tumour 
DNA in comparison to the lymphocyte DNA.
Western blotting results showed that PTEN protein was 
detected in all primary cultures tested (Supplementary Figure 
2B). The presence of PTEN in our cultures could possibly 
explain the limited efficacy of the AZD7328 and KU-0063794 
in comparison to PTEN-null cell lines, such as LNCaP.
Table 1. EC50 for AZD7328 and KU-0063794 in prostate cell lines.
Cell line Origin PTEN status EC50 [μM]
AKT inhibitor mTOR inhibitor
BPH-1 Benign prostate + >50 5.8 (3.4-8.3)
P4E6 Localised prostate tumour + >50 10.2 (7.2-13.2)
LNCaP Lymph node metastasis - 0.4 (0.3-0.5) 1.03 (0.78-1.28)
PC3 Bone metastasis - 11.0 (6.2-15.8) 0.6 (0.3-0.9)
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Treatment with AZD7328 and KU-0063794 
reduces levels of phospho-biomarkers and 
induces cell cycle arrest in LNCaP cells
In order to validate the specificity of the inhibitors 
on the PI3K/AKT/mTOR pathway, we then determined 
the activity of selected phospho-biomarkers, by western 
blotting. PTEN-positive (BPH1) and PTEN-negative 
(LNCaP and PC3) cell lines were treated with 1 μM 
AZD7328 and KU-0063794 for 2 hours. The results 
showed a reduction in phospho-PRAS40 (T246), which is 
a substrate of AKT kinase, in all the cell lines, following 
treatment with AZD7328 (Figure 2A). However, phospho-
FOXO (T24/T32) levels decreased only in LNCaP cells. 
Figure 1: Cell viability decreases following inhibition of AKT and mTOR in patient-derived prostate cultures. (A) 
Primary cultures derived from cancers (n=5) and normal prostate (n=1) were treated with either 3 μM AZD7328, 3 μM KU-0063794 or a 
combination of 3 μM AZD7328 + 3 μM KU-0063794 in triplicate for 24 hours and 48 hours. Following treatment, the cells were harvested, 
stained with trypan blue and counted. The percentage of viable cells was calculated and normalized to the vehicle control (0.04% DMSO). 
Significant differences (p value < 0.05) in cell viability are indicated on the graphs. (B) Primary prostate cancer samples H252/12, H163/12, 
H149/12, and H135/11 were treated with 3 μM AZD7328, 3 μM KU-0063297 or a combination of 3 μM AZD7328 + 3 μM KU-0063794 
for 72 hours. Following treatment, the cells were harvested, sorted into committed basal (CB), transit amplifying (TA) and stem-like cells 
(SC) and counted using trypan blue exclusion. Percentage of viable cells was calculated and normalized relative to the vehicle control 
(0.06% DMSO). Error bars represent the standard deviation. Significant difference (p <0.05) in cell viability was only observed in stem cell 
fraction treated with the combination of 3 μM AZD7328 + 3 μM KU-0063794 in comparison to vehicle control (indicated on the graph). 
(C) Cell cycle distribution remains unchanged in primary prostate cultures after treatment with AZD7328 and KU-0063794. Five prostate 
cultures (2 BPH and 3 cancers) were treated with 5 μM AZD7328, 5 μM KU-0063794 or 5 μM AZD7328 + 5 μM KU-0063794 for 72 hours. 
Following treatment, non-adherent cells were removed and remaining cells were harvested, fixed with 70% ice-cold ethanol, and stained 
with propidium iodide and analysed by flow cytometry. Control cells were treated with 0.1% DMSO. The signal was recorded in the PE 
channel and debris (subG1 phase) were excluded from the analysis.
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Treatment with KU-0063794 resulted in a significant 
reduction of phospho-S6 (S235/236) (mTORC1 substrate) 
and phospho-AKT (S473) (mTORC2 substrate) in all 
three cell lines. This result confirmed the specificity 
of the inhibitors and their efficacy at a concentration of 
1 μM, especially in LNCaP cells, where reduction of all 
respective biomarkers was observed.
Next, the effect of AKT or mTOR inhibition on 
cell cycle distribution was analysed. The results showed 
that the malignant LNCaP cells were the most affected. 
The majority of cells (86%) arrested in G0/G1 following 
72-hour treatment with 1 μM KU-0063794, and 81% 
after treatment with 1 μM AZD7328, compared to 65% 
for the vehicle control (Figure 2B). Cell cycle distribution 
in BPH1 and PC3 cells did not change significantly after 
treatment with either of the inhibitors.
Treatment of patient-derived cultures with 
AZD7328 induces autophagy and an increase in 
Phospho-ERK1/2 levels
As there was more variability in primary cultures’ 
response to low concentrations of the inhibitors, we next 
investigated whether treatment with higher concentrations 
(10 – 50 μM) would result in cell death of the patient-
derived cultures. A 72-hour treatment resulted in dramatic 
morphological changes, which were very specific for each 
inhibitor (Figure 3A). Treatment with 25 μM AZD7328 
increased vacuolation of a cancer culture (H282/12), 
indicative of autophagy (Figure 3A, middle panel). In 
contrast, treatment of the same cells with 25 μM KU-
0063794, caused membrane blebbing in a number of 
cells, indicative of apoptosis (Figure 3A, right panel). To 
Table 2: Primers used for PTEN mutational and LOH analysis.
Primer sequences/ analysis type Forward Reverse
Exon 5 sequencing (mutational 
analysis) 5’ ACCTGTTAAGTTTGTATGCAAC 3’ 5’ TCCAGGAAGAGGAAAGGAAA 3’
LOH intron 2 (AFMa086wg9) 5’ AAATGTACGGTTCATTGACTT 3’ 5’ GACTGACTACAAATGGGCA 3’
LOH intron 8 5’ CATTCTTCATACCAGGACCAG 3’ 5’ TCATGTTACTGCTACGTAAAC 3’
Figure 2: Inhibition of AKT and mTOR kinase reduces phospho-biomarker expression and induces cell cycle arrest 
in LNCaP cells. (A) Prostate cell lines BPH1, LNCaP and PC3 were treated with either 1 µM AZD7328 or 1 µM KU-0063794 for 
2 hours to measure acute response in change of biomarkers phosphorylation status. Following treatment, cells were lysed on ice, spun 
down and supernatant was collected. 20 µg of protein was loaded and run on 4-12% Bis-Tris polyacrylamide gel. Resolved protein was 
then electrotransferred to PVDF membranes and immunostained with antibodies against Phospho-AKT (S473), Phospho-FoxO1/FoxO3a 
(T24/T32), Phospho-PRAS40 (T246), Phospho-S6 (S235/236), total AKT, FoxO3a, total S6 and Vinculin, which was used as a loading 
control. Dashed line separating lane 1 (0.1% DMSO control) from the remaining 2 lanes indicates where images were cropped. (B) Cell 
cycle distribution was determined in BPH1, LNCAP and PC3 cells. Cells were treated with either 1 µM AZD7328 or 1 µM KU-0063794 for 
72 hours. Following treatment, cells were washed with PBS, then harvested, fixed with 70% ice-cold ethanol, and stained with propidium 
iodide and analysed by flow cytometry. Control cells were treated with 0.1% DMSO. The signal was recorded in the PE channel, and debris 
were excluded from the analysis.
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follow up these observations, expression of an autophagy 
marker, LC3 B was analysed by immunofluorescence. 
The results showed evidence of autophagosomes in the 
cytoplasm in the cells treated with AZD7328, but not with 
KU-0063794 (Figure 3B). Autophagy was also measured 
by Western blot; conversion of LC3B-I to LC3B-II 
is suggestive of autophagy, which was observed after 
treatment with AZD7328 (Figure 3C and 3D). In addition, 
Figure 3: Autophagy is induced and phospho-ERK1/2 levels increase in patient-derived cultures after treatment with 
AKT inhibitor. (A) Phase contrast images of primary cells (H282/13) from a Gleason 7 (4+3) prostate cancer, treated with 0.5% DMSO 
(left), 25 μM AZD7328 (middle) and 25 μM KU-0063794 (right) for 72 hours. Increased vacuolization of AZD7328-treated cells and 
membrane blebbing of KU-0063794-treated cells are indicated (red arrows). Control cells were treated with 0.5% DMSO. (B) LC3 B 
expression increases in primary prostate cancer cells H310/13 (GL7) following treatment with AZD7328. Expression of the autophagy 
marker, an LC3 B, was determined using Immunofluorescence. The cells were seeded into collagen I-coated 8-well chamber slides and 
treated with either 25 μM AZD7328 or 25 μM KU-0063794 for 96 hours and then fixed in 4% PFA. Control cells were treated with 
0.25% DMSO. Scale bar on the phase contrast images represents 200μm and on the fluorescent images 63 μm. (C) Phospho-ERK1/2 
levels increase in prostate primary cultures following treatment with AZD7328 and KU-0063794. Primary BPH (H277/13) and cancer 
cells (H278/13) were treated with 5 μM AZD7328, 5 μM KU-0063794 or 5 μM AZD7328 + 5 μM KU-0063794 for 72 hours. Westerns 
were carried out and biomarkers detected (phospho-AKT (S473), total AKT, phospho-ERK1/2 (Thr202/Tyr204), total ERK1/2 and LC3 
B). Vehicle control cells were treated with 0.1% DMSO. Staining with β-actin antibody was used as a loading control. The bands were 
quantified using Image J software and the expression normalized to the vehicle control; the values are shown below the blot. (D) Primary 
prostate cancer cells H282/13 were treated for 72 hours with up to 50 μM of AZD7328 and KU-0063794 or a 10 μM AZD7328 + 10 μM 
KU-0063794 combination of both. Westerns were carried out and biomarkers detected (phospho-AKT, total AKT, phospho-ERK1/2, total 
ERK1/2, phospho-S6, total S6, cleaved PARP and LC3 B). Vehicle control cells were treated with 0.5% DMSO. Staining with β-actin 
antibody was used as a loading control. The bands were quantified using Image J software and the expression normalized to β-actin; the 
values are shown below the blot.
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apoptosis was measured using cleaved PARP (Figure 3D). 
The results also demonstrated an increase in cleaved 
PARP levels in cells treated with AZD7328, but not KU-
0063794 (Figure 3D), suggesting that despite activation of 
autophagy, cells died via apoptosis.
Additionally, treatment with AZD7328 caused 
an increase in phospho-ERK1/2 levels in all analysed 
cultures (Figure 3C and 3D), indicating an activation of 
the MAPK pathway in those cells. Treatment with KU-
0063794 did not increase levels of phospho-ERK1/2 in 
any of the cancer cultures. However, an increase in MAPK 
pathway activity was observed in KU-0063794-treated 
BPH cultures (Figure 3C).
As EGF is an activating ligand of the MAPK 
pathway and is a component of primary cell culture media 
used in our laboratory, we sought to determine whether 
the EGF in the culture medium affected the outcome of 
treatment with the inhibitors. Selected phospho-biomarker 
levels were determined in H268/12 (BPH culture) 
following treatment with 5 μM AZD7328, 5 μM KU-
0063794 or a combination of 5 + 5. The results showed 
that treatment with AZD7328 resulted in a 9-fold increase 
in phospho-AKT in the presence of EGF, whereas in the 
absence of EGF, a 12.1-fold increase in expression was 
observed (Supplementary Figure 3). Phosphorylation of 
ERK1/2 increased by 2.8-fold following treatment with 
AZD7328 (in the presence of EGF) and by 1.2 in the 
absence of EGF, which suggests that the ERK activation 
may be mediated via signalling from growth factors, 
such as EGF. However, phosphorylation of S6 remained 
at a comparable level following treatment, either in the 
presence or absence of EGF. We concluded that addition 
of EGF to the stem cell media affected, but did not mask 
the outcome of treatment. Therefore, in subsequent 
experiments EGF was included in the culture medium for 
primary cells.
Table 3: Patient data summary.
Patient ID Operation Diagnosis (Gleason grade) Age Hormone therapy
H233/12 Radical prostatectomy Normal 61 Naive
H268/12 TURP BPH 62 -
H277/13 TURP BPH 68 -
H313/13 TURP BPH 65 -
H278/13 Radical prostatectomy Cancer - Gleason 6 (3 + 3) 72 Naive
H315/13 Radical prostatectomy Cancer - Gleason 6 (3 + 3) 62 Naive
H237/12 Radical prostatectomy Cancer - Gleason 7 (3 + 4) 66 Naive
H240/12 RA+RB Radical prostatectomy Cancer - Gleason 7 (3 + 4) 66 Naive
H252/12 Radical prostatectomy Cancer - Gleason 7 (3 + 4) 60 Naive
H310/13 R+L Radical prostatectomy Cancer - Gleason 7 (3 + 4) 67 Naive
H329/13 LB Radical prostatectomy Cancer - Gleason 7 (3 + 4) 53 Naive
H373/13 Radical prostatectomy Cancer - Gleason 7 (3 + 4) 82 Naive
H377/13 Radical prostatectomy Cancer - Gleason 7 (3 + 4) 60 Naive
H233/12 Radical prostatectomy Cancer - Gleason 7 (4 + 3) 61 Naive
H282/13 RA+RB Radical prostatectomy Cancer - Gleason 7 (4 + 3) 62 Naive
H236/12 Radical prostatectomy Cancer - Gleason 8 (4 +4) 61 Naive
H163/12 Channel TURP Cancer - Gleason 8 (4 +4) 65 Yes
H239/12 RB Radical prostatectomy Cancer - Gleason 9 (4 + 5) 50 Naive
H149/12 Channel TURP Cancer - Gleason 9 (4 + 5) 78 Yes
H224/12 Channel TURP Cancer - Gleason 9 (4 + 5) 76 Yes
H271/12 Channel TURP Cancer - Gleason 9 (4 + 5) 86 Yes
H135/11 Channel TURP Cancer - Gleason 9 (5 + 4) 56 Yes
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Combined treatment with AZD7328 and 
MEK1/2 inhibitors further enhances 
phosphorylation of ERK1/2 in patient-derived 
cultures but induces senescence
To establish whether inhibition of MEK1/2 would be 
sufficient to overcome the compensatory effect of MAPK 
pathway activation, following inhibition of AZD7328, 
two small molecule inhibitors of MEK1/2, AZD6244 
and RO-5126766, were tested. Following confirmation 
of inhibitory activity of both MEK1/2 inhibitors in 
prostate epithelial cultures (Supplementary Figure 4), 
combination treatment with AZD7328 + AZD6244 or 
AZD7328 + RO-512 were performed in patient-derived 
cancer cultures, for 72 hours. The results from Western 
blotting showed a further increase in phospho-ERK1/2 
levels after treatment with either of the combinations 
(Figure 4A and 4B), even after treatment with a high 
concentration (up to 25 µM) of the MEK1/2 inhibitors. 
This suggests that despite confirmed inhibitory activity 
against MEK1/2 kinase, neither AZD6244 nor RO-512 
inhibitor is capable of preventing ERK1/2 phosphorylation 
following compensatory activation of MAPK pathway. 
However, despite this increase in phospho-ERK1/2 
levels, the effect of combined treatment results in cellular 
senescence as detected by the acidic β-galactosidase 
staining (Figure 4C).
Combined inhibition of AKT and mTOR 
decreases tumour frequency in a patient-derived 
xenograft model
To determine whether AKT and mTOR blockade 
could inhibit tumour growth, tumour cells were harvested 
Figure 4: Senescence is induced following combination treatment with AZD7328 and MEK1/2 inhibitors. Primary cancer 
cultures were treated with a range of concentrations of AZD6244, AZD7328 or combinations of AZD6244 + AZD7328 (A) or RO-512 
+ AZD7328 (B) for 72 hours. Westerns were carried out and biomarkers detected (phospho-AKT, total AKT, phospho-ERK1/2 and total 
ERK1/2). Vehicle control cells were treated with 0.5% DMSO (A) or 0.2 % DMSO (B). The bands were quantified using Image J software 
and the expression normalized to β-actin; the values are shown below the blot. (C) Primary BPH culture H373/13 was treated with either 
1 μM AZD6244, 1 μM RO-512 or a combination of 1 μM AZD6244 + 1 μM AZD7328 or 1 μM RO-512 + 1 μM AZD7328 for 72 hours. 
Following treatment, cells were fixed and stained according to the manufacturer’s instructions and phase contrast images were taken. 
β-galactosidase – positive cells were observed (red arrows) as well as β-galactosidase negative cells (green arrows). Vehicle control cells 
were treated with 0.02% DMSO. Scale bar represents 400 μm.
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from a human prostate cancer xenograft, (derived from a 
patient with hormone-naïve Gleason 7 disease), and were 
subsequently treated with either 10 μM AZD7328, 10 μM 
KU-0063794 or a combination of 10 + 10, for 72 hours. 
Following treatment, the cells were engrafted (at limiting 
dilutions) into Rag2-/-γC-/-mice to determine the effect of 
treatment on tumour frequency. The results showed that 
xenograft tumour cells were still able to initiate tumours 
following treatment with either inhibitor or a combination 
of both (Table 4). However, tumour frequency was 
significantly reduced with the combination treatment (P 
=0.010) (Table 5). In contrast, neither AZD7328 nor KU-
0063794 blockade affected tumour outgrowth.
An additional effect of treatment with a combination 
of the inhibitors was an 8-day increase in the tumour 
latency compared to vehicle control (38 days and 30 days, 
respectively). There was no difference in tumour latency 
following treatment with either inhibitor alone.
DISCUSSION
The PI3K/AKT/mTOR and the Androgen Receptor 
signalling pathways are important drivers of prostate 
cancer growth and progression. Despite progress in 
prostate cancer treatment with the development of second 
generation anti-androgen agents, patient outcome remains 
unsatisfactory. Following the development of endocrine 
resistance, patients are typically treated with docetaxel, 
which is effective in 40 – 55 % of patients [4, 35–37]. 
Targeting of the PI3K/AKT/mTOR pathway has been 
investigated in a number of studies as an alternative 
treatment for patients with over-activation of the pathway 
[38, 39]. Since a reciprocal feedback between the 
AR and the PI3K pathways has been demonstrated in 
prostate cancer, a combination of inhibitors targeting the 
PI3K pathway and anti-androgens, such as abiraterone 
and enzalutamide is currently in clinical trials [8, 40]. 
However, targeting androgen-dependent prostate cells 
does not eradicate the stem cell component of prostate 
tumours, which we and others have shown to have an AR-
negative phenotype [24, 28, 41]. Therefore alternative 
combinations of drugs are urgently required if we are 
to progress in the treatment of prostate cancer and the 
potential of PI3K pathway inhibitors has to be fully 
elucidated.
The aim of this study was to determine the 
importance of the PI3K/AKT/mTOR pathway in human 
prostate cancer. This was performed by targeting the 
pathway with AKT and mTOR inhibitors in prostate 
cancer cell lines, primary cell cultures and a ‘near-patient’ 
xenograft. Activity of the small molecule inhibitors against 
AKT and mTOR kinases used in this study have also been 
tested in a number of other tumour types [42, 43].
The results of treatment with AZD7328 and KU-
0063794 showed that PTEN-negative LNCaP cells were 
the most susceptible to treatment. Treatment of primary 
cultures (derived from patients with BPH and cancer) 
confirmed variability in response between patient samples, 
even from patients with the same Gleason grade. In 
contrast to established prostate cancer cell lines, PTEN 
Table 4: Tumour initiation frequency is lower in xenograft cells treated with a combination of AKT and mTOR 
inhibitor.
Number of inoculated 
cells
10 000 cells 1000 
cells
100 cells 10 cells 1 cell Tumour initiation 
frequency
(95% CI)Treatment
0.2% DMSO 2/2 2/2 2/2 1/2 0/2 16.6 (98.9-3.16)
10 µM AZD7328 2/2 2/2 2/2 0/2 0/2 43.8 (201.1-9.84)
10 µM KU-0063794 2/2 2/2 2/2 1/2 0/2 16.6 (98.9-3.16)
10 +10 combination 2/2 2/2 0/2 0/2 0/2 434.6 (2008.4-94.36)
Table 5: Pairwise tests for differences in tumour frequencies.
Group 1 Group 2 p value
AZD7328 Combination 0.071
AZD7328 DMSO 0.443
AZD7328 KU-0063794 0.443
Combination DMSO 0.010
Combination KU-0063794 0.010
DMSO KU-0063794 1
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protein expression was observed in all primary cells 
investigated, including Gleason 8 tumours. Although 
there was variability in the levels of PTEN expression, 
none of the cultures showed a complete loss of PTEN. 
However, 3 out of 7 (43%) patient-derived cultures had 
mutations in exon 5 of the PTEN gene and 2 out of 7 
(28.6%) showed loss of heterozygosity in tumour DNA, 
in comparison to matched lymphocyte DNA. PTEN loss 
is typically observed in 70-80% of castration resistant 
prostate tumours [32, 33, 44]. This discrepancy can be 
explained because the majority of cultures used in this 
study were derived from treatment naïve patients with 
early stage disease, whereas PTEN is more frequently 
lost in advanced prostate cancers. Only 12% of radical 
prostatectomy samples show complete loss of PTEN 
[45]. Nevertheless these cultures are relevant because it 
is imperative that combinations of inhibitors that delay 
progression to advanced disease, after initial androgen 
deprivation therapy or radiotherapy, are identified.
Targeting the PI3K/AKT/mTOR pathway has 
been proposed as a clinical strategy to eliminate cancer 
stem cells. For example, treatment of anaplastic thyroid 
cancer with a PI3K inhibitor, LY294002, attenuated 
the self-renewal of cancer stem cells and induced cell 
differentiation [46]. Similar findings were also reported in 
acute myeloid leukaemia and in breast cancer stem cells, 
where it was shown that the PI3K/AKT/mTOR pathway 
was critical for cancer stem cell proliferation and survival 
[47, 48]. Moreover, treatment with a chemotherapeutic 
drug cisplatin, results in a significant increase in breast 
cancer stem cells, which could be partially attributed to 
the activation of the PI3K/AKT/mTOR pathway [49]. 
However, combined treatment with cisplatin and the 
mTOR inhibitor rapamycin synergistically inhibited 
cancer stem cell-mediated primary and metastatic cancer 
growth [49]. These recent findings emphasise the need 
to test combination treatments, as a more successful 
approach to targeting cancer stem cells. Our findings 
suggest that despite differences between patients’ 
responses, targeting stem cells with a combination of 
AZD7328 and KU-0063794 might potentially be more 
successful than a monotherapy with either drug alone. 
Further investigation is needed to identify differences 
between treatment responders and non-responders, in a 
more efficient stratification of patients in the clinic.
Treatment with high concentrations (≥ 25 μM) 
of AKT and mTOR inhibitors induced dramatic 
morphological changes, such as vacuolation of cells and 
membrane blebbing. Although these concentrations are 
much higher than exposures achieved in man by AKT and 
mTOR inhibitors of similar potency, the biology invoked 
as a consequence of greater target inhibition is of interest. 
Membrane blebs are spherical outgrowths of the plasma 
membrane that occur upon membrane detachment from 
the underlying cytoskeleton and are indicative of apoptosis 
[50]. However, we observed no increase in cleaved PARP 
expression after mTOR inhibitor treatment. This could be 
due to a minority of cells showing apoptotic features, and 
therefore being undetectable by western blotting. Increased 
vacuolation of cells following treatment with the AKT 
inhibitor was morphologically indicative of autophagy 
and the formation of autophagosomes. Autophagy is 
a cellular catabolic degradation process in response to 
starvation or stress, in which cellular organelles, proteins 
and cytoplasm are digested and recycled to maintain 
metabolism [51, 52]. A clear increase in the conversion of 
LC3-B I to LC3-B II (autophagy marker) demonstrated by 
both western blotting and immunofluorescence confirmed 
the morphological evidence. Treatment with the ATP-
competitive AKT inhibitor (AZD7328) does induce 
autophagy in human bladder cancer cell lines, which can 
be overcome by treating the cells with chloroquine [53]. 
However, autophagy can also prevent tumourigenesis, 
acting as a tumour suppressor [52, 54]. Accumulation of 
the autophagy substrate p62/SQSTM1 is sufficient to both 
activate the MAPK pathway and increase cell proliferation 
in PI3K-expressing mammary 3D structures [54]. 
Increased cell proliferation and MAPK activation, due to 
inhibition of autophagy, was only evident under 3D culture 
conditions, and not in monolayer cells [54]. In 3D, the cells 
treated with AZD7328 showed the expected increase in 
autophagy, as well as activation of the MAPK pathway.
We observed activation of the MAPK pathway 
following treatment with AZD7328, and so the primary 
cultures were also treated with a combination of AZD7328 
and MEK1/2 inhibitors to determine the outcome of 
inhibiting this compensatory pathway. Surprisingly, a 
combined treatment with AZD7328 and either AZD6244 
or RO-512 resulted in an increased phosphorylation 
of ERK1/2 to even greater levels than treatment with 
AZD7328 alone. Davies and colleagues have previously 
demonstrated activity and efficiency of the AZD6244 
in a large panel of human cancer cell lines as well as in 
xenografts derived from them [55]. It has been reported 
that a majority of cell lines with a mutation in KRAS, 
NRAS or BRAF genes showed a significantly increased 
sensitivity to MEK inhibition, resulting in cell growth 
inhibition and induction of apoptosis [55]. In the human 
colon carcinoma xenograft HCT-116, a combination 
treatment of the AZD6244 and docetaxel resulted in 
enhanced tumour growth inhibition, in comparison to 
monotherapy [56]. However, the rate of mutations in Ras/
MEK/ERK pathway in clinical prostate cancer is very low; 
only up to 7% of clinical samples have activating point 
mutations of Ras and around 4 % are positive for BRAF, 
the most common activating mutation of RAF [57]. 
Similarly, efficacy of RO-512 has been demonstrated in 
a number of human cancer cell lines and also in the HCT-
116 xenograft model [58]. However, in our patient-derived 
cultures, neither of the MEK1/2 inhibitors was able to 
overcome the compensatory ERK1/2 activation caused by 
inhibition of AKT.
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It is unclear why combination treatment of prostate 
cancer primary cells with AZD7328 and MEK1/2 inhibitors 
did not reduce ERK1/2 phosphorylation. A possible 
explanation is that we could be observing a profound stress 
response where other MAPKs are activated and although 
phospho-ERK1/2 antibody we used does not cross-react with 
the corresponding phosphorylated residues of either JNK/
SAPK or p38 MAP kinases, this phenomenon will have to 
be investigated further. However, acidic β-galactosidase 
staining of treated cultures revealed that the cells became 
senescent after the combination treatment. Senescence is 
frequently triggered in tumours in response to chemotherapy 
and radiotherapy treatment in cancer patients [59, 60] and 
it has been demonstrated that PTEN-loss-induced cellular 
senescence inhibits tumorigenesis in vivo in a human xenograft 
model of prostate cancer [61]. Induction of senescence in 
cancer cells could indeed be a good therapeutic strategy for 
treatment of prostate cancer if it established stable disease [61].
The PI3K/AKT/mTOR and the Ras/MEK/ERK 
pathways are the two major hyper-activated pathways, which 
promote cell proliferation, survival and metastasis in human 
cancer [11, 62]. Significant activation of MAPK signalling 
has been observed in both primary and in metastatic cancer 
[63]. Activation of the MAPK pathway has been implicated 
in resistance to the PI3K/AKT/mTOR signalling inhibition in 
other studies [64]. Here, we present for the first time, evidence 
that the MAPK pathway acts as a compensatory pathway 
in primary prostate epithelial cell cultures following AKT 
inhibition. However, the possibility of a third compensatory 
pathway cannot be discounted by our data.
Despite our observation that the Ras/MEK/ERK 
compensatory pathway is activated in primary cells 
following the PI3K/AKT/mTOR inhibition, the ex vivo 
treatment of the PDX with a combination of KU-0063794 
(mTOR inhibitor) and AZD7328 (AKT inhibitor) showed 
an effective reduction in tumour outgrowth. Therefore 
this combination treatment alongside anti-androgen 
therapy has the potential to be more effective than single 
treatments. However, due to the compensatory pathway 
and the further possibility of as yet unknown effects, the 
outcome of drug combinations may not be predictable and 
may have to be determined on a patient specific basis. The 
utilisation of primary cell cultures from multiple individual 
patients will allow elucidation of mechanisms of action of 
drugs, mechanisms of resistance and variation in patient 
response, at a level of which cannot be predicted using the 
standard panel of available prostate cancer cell lines.
MATERIALS AND METHODS
Inhibitors
The AKT inhibitor AZ7328, mTOR inhibitor KU-
0063794 and MEK inhibitor Selumetinib (AZD6244; 
ARRY-142886) were obtained from AstraZeneca, and the 
MEK1/2 inhibitor RO-5126766 (RO-512) was purchased 
from MedKoo Biosciences, Inc., NC, USA. AZ7328 is 
an ATP-competitive, selective inhibitor of AKT [53] that 
inhibits all three AKT isoforms with an IC50 of < 50 nM in 
isolated enzyme assays, and inhibits the phosphorylation 
of GSK3β in PTEN null MDA-MB-468 breast cancer 
cells with an IC50 of 91 nM. KU-0063794 is a highly 
selective inhibitor of mTOR kinase [43] and Selumetinib 
is a selective, non-ATP competitive inhibitor of MEK1/2 
kinases [55]. RO-5126766 is an allosteric MEK inhibitor 
which has been shown to additionally supress feedback 
induction of RAF-dependent MEK phosphorylation [58].
Culture of cell lines
Human prostate cell lines used in the experiments 
included: BPH1, P4E6, LNCaP and PC3 cells. LNCaP and 
PC3 cells were purchased from American Type Culture 
Collection (ATCC), BPH1 were a gift from Dr Hayward 
(NorthShore University HealthSystem Research Institute), 
and P4E6 cells were derived in our laboratory [65]. BPH1 
and LNCaP cells were cultured in Roswell Park Memorial 
Institute-1640 (RPMI) (Invitrogen Ltd) supplemented with 
5% or 10% Foetal Calf Serum (FCS) (PAA), respectively, 
and 2 mM L-Glutamine (Invitrogen Ltd). PC3 cells were 
cultured in Ham’s F-12 medium (Lonza) supplemented 
with 7% FCS and 2 mM L-Glutamine. P4E6 cells were 
cultured in Keratinocyte Serum-Free Medium (KSFM) 
(Invitrogen Ltd) supplemented with 2% FCS, 2 mM 
L-Glutamine, 5 ng/ml Epidermal Growth Factor (EGF), 
50 μg/ml bovine pituitary extract (Invitrogen Ltd). All 
cell lines were cultured in T25 or T75 cell culture flasks 
(Corning) at 37°C in 5% CO2.
Tissue collection and culture of tumour cells
Prostate tissue was obtained from patients 
undergoing radical prostatectomy or transurethral 
resection of the prostate (TURP) (Table 3), with informed 
patient consent and approval from the local Research 
Ethics Committee (07/H1304/121). All patient samples 
were anonymized. Epithelial cultures were prepared as 
described previously [31]. Cell cultures were maintained 
in stem cell media (SCM), which consisted of keratinocyte 
growth medium supplemented with 5 ng/ml Epidermal 
Growth Factor (EGF), 50 μg/ml bovine pituitary extract 
(Invitrogen Ltd), 2 ng/ml stem cell factor (First Link), 100 
ng/ml cholera toxin (Sigma-Aldrich Company Ltd) and 1 
ng/ml GM-SCF (First Link). Epithelial cells were cultured 
on collagen I – coated plates in the presence of irradiated 
(60 Gy) STO (mouse embryonic fibroblasts) cells.
Generation of xenografts and isolation of tumour 
cells for ex-vivo treatment
All animal work was approved by the University 
of York Animal Procedures and Ethics Committee 
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and performed under a United Kingdom Home Office 
License. Human prostate cancer tissue was obtained from 
a patient with hormone naïve, Gleason 7 disease. Tumour 
Xenografts were derived according to the method outlined 
in Kroon et al., 2013 [66]. Xenografts were maintained 
subcutaneously in BALB/c/Rag2-/-γC-/- mice, which are 
highly receptive for engrafting of human tissue due to 
deficiencies in T, B and NK cell development [67].
15 mm3 tumours were harvested from humanely 
euthanized mice and human Lin-/CD31-, were isolated 
according to Kroon et al., 2013 [66]. Tumour cells 
were resuspended in D10 medium, plated onto collagen 
I – dishes and treated for up to 72 hours with AKT and 
mTOR inhibitors. Following treatment, the cells were 
resuspended in Matrigel and injected subcutaneously into 
the flanks of a Rag2-/-γC-/-, 2x105 irradiated STO were used 
as carrier cells. Mice were monitored weekly for tumour 
growth. Once the tumours were detectable they were 
measured every 2-3 days using a digital calliper (Duratool 
DC150). Tumour volume (mm3) was calculated using the 
ellipsoidal formula: (length x width2)/2. Tumour initiation 
frequency was calculated using Extreme Limiting Dilution 
Analysis software available online at (http://bioinf.wehi.
edu.au/software/elda/), which provided an estimate of 
frequency with 95% confidence intervals and includes 
the Pearson’s chi-square test for pairwise analysis to 
determine differences between treatment groups.
Treatment of subpopulations of primary cell 
cultures
Primary cells were seeded onto collagen I-coated 
10 cm dishes, 24 hours prior to treatment. Cells were 
treated with increasing concentrations (0.1 μM to 50 
μM) of AZD7328, KU-0063794 or MEK1/2 inhibitors 
either alone or in combination for up to 72 hours. Control 
cells were treated with DMSO. Following treatment, 
α2β1
hi/CD133+(stem-like cells), α2β1
hi/CD133- (transit 
amplifying, TA) and α2β1
low (committed basal, CB) 
cells were isolated by MACS (Miltenyi Biotec Ltd.), as 
described previously [68, 69]. Briefly, cell subpopulations 
were enriched and selected from primary cell cultures, 
first using collagen adherence to separate α2β1
hi and α2β1
low 
cells. This was followed by incubating the α2β1
hi cells with 
anti-human CD133 microbeads and selecting CD133+ 
cells using MACS magnetic bead selection (Miltenyi 
Biotec Ltd). This results in three cell subpopulations – 
α2β1
hi/CD133+(stem-like cells), α2β1
hi/CD133- (transit 
amplifying, TA) and α2β1
low (committed basal, CB) cells.
PTEN mutational analysis and loss of 
heterozygosity (LOH) analysis
The Polymerase chain reaction (PCR) was used to 
amplify matched lymphocyte and tumour DNA from the 
patient primary cultures to determine mutational status 
and loss of heterozygosity of the PTEN gene. Standard 
PCR conditions were adapted for the analysis of PTEN 
exon 5 [34]. PCR products were column purified using 
Qiagen Quick PCR clean up kit (Qiagen, UK) and then 
directly sequenced using PTEN exon 5 sequencing primers 
(Table 2). The presence of mutations was determined by 
using EditSeq software (DNASTAR).
Loss of heterozygosity in PTEN was assessed 
using two LOH probes described in Dahia et al 
[34]; they included a dinucleotide repeat in PTEN 
intron 2 (AFMa086wg9) (probe 1) and a G/T sequence 
polymorphism in PTEN intron 8 (probe 2). The reverse 
primer for intron 2 was labelled with a JOE fluorescent 
dye enabling PCR fragment analysis, which was 
performed using Applied Biosystems ABI3130XL 
and data analysed using Gene Mapper software (Life 
Technologies). LOH was identified in the heterozygous 
tumour samples as a reduction in one of the peaks, which 
corresponded to one of the alleles of the PTEN gene. The 
G/T polymorphism was analysed using digestion with 
restriction enzyme HincII (New England Biosciences), 
where the polymorphism is differentially cleaved in 
heterozygous and homozygous individuals.
Agarose gel electrophoresis
PCR products were visualised using 1.5% agarose 
gel electrophoresis prepared with Tris-Acetate-EDTA 
buffer and run at 80V. The products of the HincII digestion 
reaction were separated in a 3% agarose gel in Tris-Borate-
EDTA buffer and run at 100V.
SDS-PAGE and Western blotting
Adherent and non-adherent cells were harvested 
and resuspended in Cytobuster protein extraction reagent 
(Novagen) supplemented with the addition of protease 
inhibitor cocktail (Roche) and phosphatase inhibitor 
cocktail (Roche). Whole cell protein lysates were 
quantified using the Bicinchoninic acid assay (BCA) 
protein assay kit (Thermo Scientific), according to 
manufacturer’s instructions.
20 μg of total cell lysate was heated to 100°C 
for 10 min in sample buffer (4 x SDS loading buffer 
(10% (v/v) glycerol, 62.5 mM Tris-HCl pH 6.8, 1% 
(w/v) SDS, 65 mM DTT and bromophenol blue), 
and subjected to PAGE and electrotransfer onto 
Immobilon-P membrane (Millipore). Membranes were 
blocked for 1 hr with 10% blocking reagent (Roche) 
in TBS-Tween, followed by incubation with primary 
antibodies at 4°C for 2 hours or overnight. Antibodies 
were purchased from Cell Signaling Technology, unless 
otherwise specified, and included: AKT (pan) (#4691), 
phospho-AKT (Thr308) (#2965), phospho-AKT 
(Ser473) (#4060), 4E-BP1 (#9452), phospho-4E-BP1 
(Thr37/46) (#2855), p44/42 MAPK (ERK1/2) (#4695), 
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phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) 
(#4370), LC3-B (abcam, ab51520), PRAS40 (#2691), 
phospho-PRAS40 (Thr246) (#2997), PTEN (#9188), S6 
Ribosomal Protein (2217), phospho-S6 (Ser235/236) 
(#2211), FoxO3a (#9467), phospho-FoxO1 (Thr24)/
FoxO3a (Thr32) (#9464), Vinculin (Sigma V9131), 
β-actin (Sigma, A4700). Chemiluminescent detection 
was performed using the BM Chemiluminescence 
Blotting Substrate (POD) system (Roche). Labelled 
proteins were visualised using ECL Hyperfilm 
(Amersham) and manually processed using Kodak GBX 
developer and fixer solutions (SLS).
Flow cytometry and cell cycle analysis
Cell lines and primary prostate cells were used for 
cell cycle analysis following treatment. Cells were fixed 
in ice-cold 70% Ethanol, then incubated on ice for 30 
minutes and resuspended in PBS. RNase A (at 1 mg/ml 
final concentration) and propidium iodide (PI; 400 µg/ml 
final concentration) were added, and cells incubated at 
37°C for 30 min. Cells were then placed on ice, analysed 
on a CyAn ADP flow cytometer (Dako Cytomation) 
and PI fluorescence was recorded in the PE channel. 
To prevent bleaching of the fluorescence, samples 
were protected from light where possible during the 
procedure. The results were analysed using the Summit 
v4.3 software.
Immunofluorescence
Primary prostate cells were seeded at a density of 
7.5 x 104 per well in BD-Biocoat collagen I-coated 8-well 
chamber slides and incubated at 37°C at 5% CO2 for 24 
hours before treatment. Following treatment, cells were 
fixed, permeabilised and stained as described previously 
[69]. Antibodies used were LC3-B (abcam, ab51520 
at 1:2000) and secondary anti-rabbit Alexa Fluor 488 
(Invitrogen, A-11034 at 1:300). Slides were mounted in 
Vectashield containing DAPI (Vector laboratories). Images 
were captured using a Nikon Eclipse TE300 fluorescent 
microscope (Nikon). Secondary only antibodies, where 
the primary antibody was replaced with PBS, were used 
as controls.
β-Galactosidase staining assay
Cells were seeded onto 10 cm dishes and, following 
treatment, an acidic β-Galactosidase assay (Cell 
Signaling Technology) was performed as an indicator of 
senescence. Briefly, cells were washed once with PBS 
and fixed for 15 minutes at room temperature, washed 
twice with PBS, and then incubated with β-Galactosidase 
staining solution, at pH 6.1, overnight at 37°C in a dry 
incubator. The staining results were analysed using an 
Evos XL transmitted light microscope (AMG) at 10x and 
20x magnification.
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